Alzheimer’s research has faced criticism from biotech insider Charles Piller in his recent book “How the ‘amyloid mafia’ took over Alzheimer’s research.” However, renowned neurologist Dennis J. Selkoe and others have vigorously defended their work, arguing that a focus on amyloid is not a conspiracy.
Contrary to Piller’s claims, no “amyloid cabal” exists, and many researchers are working on various aspects of Alzheimer’s disease. While it is true that some cases of fraudulent research have occurred, these instances do not negate the progress made in understanding the amyloid mechanism. In fact, numerous studies have demonstrated a causal link between amyloid levels and the progression of Alzheimer’s.
The evidence supporting an early role for amyloid in driving tau and inflammation is strong. Genetic alterations linked to Alzheimer’s disease have been proven to induce brain pathology and clinical symptoms. Elevated brain amyloid levels in cognitively normal older individuals more than double their risk of progressing to symptomatic Alzheimer’s over just five years.
Anti-amyloid treatments, such as lecanemab and donanemab, have been approved by regulatory bodies worldwide and have shown significant benefits in slowing cognitive decline and daily function. These treatments are designed to target a key cause of the disease, and their effects have been proven through rigorous testing.
Piller’s criticism is misplaced, as biopharma companies prioritize testing theories that work therapeutically, regardless of the researcher behind them. While no treatment is perfect, anti-amyloid drugs have generally been safe, with rare but serious side effects. The scientific community has taken steps to address these concerns and ensure patient safety.
Ultimately, science demands scrutiny and skepticism, but it also requires a commitment to evidence-based research. Piller’s misconceptions about Alzheimer’s research will not be won on the facts; instead, we must continue to advance our understanding of this complex disease using rigorous testing and open-minded dialogue.
Source: https://www.statnews.com/2025/02/14/alzheimers-doctored-charles-piller-amyloid-hypothesis